{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:27:37Z","timestamp":1791084457265,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"DOI":"10.2146\/ajhp150727","type":"journal-article","created":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T19:56:18Z","timestamp":1463860578000},"page":"821-830","source":"Crossref","is-referenced-by-count":23,"title":["The role of specialty pharmacy drugs in the management of inflammatory diseases"],"prefix":"10.1093","volume":"73","author":[{"given":"Kelly A.","family":"Mullican","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J.","family":"Francart","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102513401900_b1-ajhp821","unstructured":"Express Scripts. 2014 drug trend report. http:\/\/lab.express-scripts.com\/drug-trend-report (accessed 2015 Aug 18)."},{"key":"key\n\t\t\t\t2019041102513401900_b2-ajhp821","unstructured":"Patient Access Network Foundation. Home page. www.panfoundation.org\/ (accessed 2015 Nov 11)."},{"key":"key\n\t\t\t\t2019041102513401900_b3-ajhp821","unstructured":"HealthWell Foundation. Ways to give. www.healthwellfoundation.org\/ways-to-give?gclid=CjwKEAiA1JuyBRCogJLz4J71kj0SJADsd6QRvh87WVC5fL-A-yf-OxhXkLgNO4zsAX3me0SZ1ou0RRoCEQPw_wcB (accessed 2015 Nov 11)."},{"key":"key\n\t\t\t\t2019041102513401900_b4-ajhp821","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t2019041102513401900_b5-ajhp821","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019041102513401900_b6-ajhp821","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041102513401900_b7-ajhp821","unstructured":"Centers for Disease Control and Prevention. Recommended adult immunization schedule, United States 2014. www.cdc.gov\/vaccines\/schedules\/downloads\/adult\/adultschedule.pdf (accessed 2015 Nov 18)."},{"key":"key\n\t\t\t\t2019041102513401900_b8-ajhp821","first-page":"1","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"National Center for Immunization and Respiratory Diseases","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t2019041102513401900_b9-ajhp821","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t2019041102513401900_b10-ajhp821","first-page":"689","article-title":"Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention to anti-tumor necrosis factor: a large retrospective study","volume":"34","author":"Den Broeder","year":"2007","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041102513401900_b11-ajhp821","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept, and anakinra treatments for rheumatoid arthritis: meta-analysis of randomized placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019041102513401900_b12-ajhp821","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3109\/s10165-012-0683-0","article-title":"Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicenter Tocilizumab in Perioperative Period (TOPP) study","volume":"23","author":"Momohara","year":"2013","journal-title":"Mod Rheumatol"},{"key":"key\n\t\t\t\t2019041102513401900_b13-ajhp821","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States\u2014part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041102513401900_b14-ajhp821","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t2019041102513401900_b15-ajhp821","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041102513401900_b16-ajhp821","volume-title":"Humira (adalimumab) injection package insert","year":"2002"},{"key":"key\n\t\t\t\t2019041102513401900_b17-ajhp821","volume-title":"Cimzia (certolizumab pegol) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041102513401900_b18-ajhp821","volume-title":"Enbrel (etanercept) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041102513401900_b19-ajhp821","volume-title":"Simponi (golimumab) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041102513401900_b20-ajhp821","volume-title":"Remicade (infliximab) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102513401900_b21-ajhp821","volume-title":"Orencia (abatacept) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102513401900_b22-ajhp821","volume-title":"Actemra (tocilizumab) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041102513401900_b23-ajhp821","volume-title":"Rituxan (rituximab) package insert","year":"2014"},{"key":"key\n\t\t\t\t2019041102513401900_b24-ajhp821","volume-title":"Kineret (anakinra) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041102513401900_b25-ajhp821","volume-title":"Xeljanz (tofacitinib) package insert","year":"2012"},{"key":"key\n\t\t\t\t2019041102513401900_b26-ajhp821","volume-title":"Stelara (ustekinumab) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041102513401900_b27-ajhp821","volume-title":"Cosentyx (secukinumab) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102513401900_b28-ajhp821","volume-title":"Otezla (apremilast) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102513401900_b29-ajhp821","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn\u2019s disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t2019041102513401900_b30-ajhp821","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00365529509096316","article-title":"Disease activity courses in a regional cohort of Crohn\u2019s disease patients","volume":"30","author":"Munkholm","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t2019041102513401900_b31-ajhp821","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102513401900_b32-ajhp821","volume-title":"Entyvio (vedolizumab) package insert","year":"2014"},{"key":"key\n\t\t\t\t2019041102513401900_b33-ajhp821","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00296-002-0237-4","article-title":"Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis","volume":"23","author":"Feldtkeller","year":"2003","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t2019041102513401900_b34-ajhp821","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s102380300000","article-title":"The treatment of ankylosing spondylitis","volume":"2","author":"Scalapino","year":"2003","journal-title":"Clin Exp Med"},{"key":"key\n\t\t\t\t2019041102513401900_b35-ajhp821","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.berh.2014.10.011","article-title":"Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biological and non-biological DMARDs","volume":"28","author":"Soriano","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key\n\t\t\t\t2019041102513401900_b36-ajhp821","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"Van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019041102513401900_b37-ajhp821","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019041102513401900_b38-ajhp821","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102513401900_b39-ajhp821","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041102513401900_b40-ajhp821","unstructured":"Medical and Media Marketing. The pipeline report 2015: dream drugs. www.mmm-online.com\/features\/the-pipeline-report-2015-dream-drugs\/article\/383894\/2\/ (accessed 2015 Aug 15)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/11\/821\/28334626\/ajhp0821.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T09:23:22Z","timestamp":1567934602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/11\/821\/5101522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150727","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6,1]]},"published":{"date-parts":[[2016,6,1]]}}}